Argentina is one of Latin America's largest and most experienced clinical trial markets. ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) targets a decision on submitted clinical trial documents within a 90-business-day statutory window that FIH/EFS device studies often exceed due to clock pauses for agency queries (RFIs). Independent ethics committees plus provincial oversight (e.g., Buenos Aires) provide rigorous review. With bioaccess® coordination, sponsors generate FDA-submissible data at ~30% lower cost than US/EU programs.
Argentina is one of the largest and most experienced clinical research markets in Latin America, with a deep base of investigators, teaching hospitals, and sponsor experience across therapeutic areas. Its regulatory authority, ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), is well-established and internationally engaged.
For clinical trials, ANMAT operates under a 90-business-day statutory review target. The clock pauses whenever the agency issues objections or queries (RFIs), and FIH/EFS device studies commonly exceed the 90-day target as a result — so 90 business days is a planning framework, not a guaranteed total start-up time. In parallel, an independent ethics committee must approve the protocol, and provincial jurisdictions such as Buenos Aires provide additional oversight — all under ISO 14155 and the Declaration of Helsinki.
bioaccess® coordinates ANMAT submissions, ethics committee review, provincial requirements, site qualification, and monitoring so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program. Argentina fits both single-country and multi-country LATAM strategies.
ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is Argentina's national regulatory authority for medicines, medical devices, and clinical research. For clinical trials, ANMAT operates under a 90-business-day statutory review target; the clock pauses for agency queries (RFIs), and FIH/EFS device studies frequently exceed the target as a result. bioaccess® prepares complete ANMAT dossiers and manages responses to agency questions.
In addition to ANMAT authorization, an independent ethics committee must approve each clinical protocol under ISO 14155 (the FDA-recognized GCP standard for medical device investigations). Ethics review evaluates scientific merit, risk-benefit balance, informed consent adequacy, and patient protection. bioaccess® coordinates ethics submissions with experienced partner committees.
Argentine provinces — most notably Buenos Aires — provide additional jurisdictional oversight of clinical research conducted within their territory. bioaccess® manages the provincial requirements in parallel with ANMAT and ethics submissions so site activation stays on the critical path.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Argentina for IDE submissions and marketing applications when studies are conducted under ISO 14155 with proper ANMAT authorization and ethics approval. bioaccess® designs every protocol for FDA submission from day one — with source data verification, monitoring plans, and documentation practices built around 21 CFR expectations.
| Metric | Argentina 🇦🇷 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory decision | ANMAT: 90-business-day statutory target (clock pauses apply) | 6–12 months (IDE + IRB) | 3–6 months (per-country CA + EC) |
| Regulatory authority | ANMAT | FDA | EMA / national CAs |
| Ethics review | Independent EC + provincial oversight | Local IRBs | Per-country ECs |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
| Investigator base | Large, experienced | Established | Established |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is Argentina's national regulatory authority for medicines, medical devices, and clinical trials.
ANMAT has a 90-business-day statutory review target for clinical trial submissions. The clock pauses when the agency raises objections or queries (RFIs), and FIH/EFS device studies often exceed the 90-day target — treat it as a planning target, not a guaranteed total.
Yes. An independent ethics committee must approve the protocol under ISO 14155, and provincial jurisdictions such as Buenos Aires also provide oversight.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Argentina when studies are conducted under ISO 14155 with proper ANMAT authorization and ethics approval. bioaccess® designs protocols for FDA submission from the start.
Argentina programs typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
Argentina combines a defined ANMAT pathway with a 90-business-day statutory review target, one of LATAM's deepest investigator bases, independent ethics review, and ~30% lower program cost than US/EU baselines.
All countries we serve · Contact bioaccess® · First-in-Human CRO